menu
    • menu
    [{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2025","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Grunenthal \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal \/ Apotex Inc"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"},{"orgOrder":0,"company":"The Valens Company","sponsor":"Valens Company","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"||TRPV1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Valens Company","highestDevelopmentStatusID":"15","companyTruncated":"The Valens Company \/ Valens Company"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Capsaicin

    Menu

    Capsaicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Grunenthal

    Germany arrow
    Pharma Live Expo
    Not Confirmed

    Grunenthal

    Germany arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Apotex Inc

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Apotex Licenses Exclusive Canadian Rights to Qutenza from Grünenthal

    Details : Apotex will have the exclusive Canadian rights to Qutenza (capsaicin), a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

    Product Name : Qutenza

    Product Type : Plant Extract/Herbal

    Upfront Cash : Undisclosed

    February 24, 2025

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Apotex Inc

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Averitas Pharma

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Averitas Pharma

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Grunenthal

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial

    Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.

    Product Name : Qutenza

    Product Type : Plant Extract/Herbal

    Upfront Cash : Inapplicable

    July 11, 2024

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Grunenthal

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Propella Therapeutics

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Propella Therapeutics

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Capsaicin

    Therapeutic Area : Musculoskeletal

    Study Phase : Phase II

    Sponsor : Aosaikang Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)...

    Details : Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.

    Product Name : CGS-200-5

    Product Type : Plant Extract/Herbal

    Upfront Cash : Undisclosed

    July 04, 2022

    Lead Product(s) : Capsaicin

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Phase II

    Sponsor : Aosaikang Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Averitas Pharma

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Averitas Pharma

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain

    Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

    Product Name : Qutenza

    Product Type : Plant Extract/Herbal

    Upfront Cash : Inapplicable

    October 08, 2021

    Lead Product(s) : Capsaicin

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    The Valens Company

    Canada arrow
    Pharma Live Expo
    Not Confirmed

    The Valens Company

    Canada arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Capsaicin,Cannabidiol

    Therapeutic Area : Musculoskeletal

    Study Phase : Approved FDF

    Sponsor : Valens Company

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand

    Details : LivRelief is a growing line of cannabis-infused topical creams created using natural ingredients which utilize a proprietary transdermal delivery system, allowing cannabinoids to reach targeted areas and designed for deep penetration.

    Product Name : LivRelief

    Product Type : Plant Extract/Herbal

    Upfront Cash : Undisclosed

    July 28, 2021

    Lead Product(s) : Capsaicin,Cannabidiol

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Approved FDF

    Sponsor : Valens Company

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth